ALLO - Allogene Therapeutics Inc. (ALLO) Q4 2023 Earnings Call Transcript
2024-03-14 20:49:03 ET
Allogene Therapeutics, Inc. (ALLO)
Q4 2023 Earnings Call Transcript
March 14, 2024, 05:00 PM ET
Company Participants
Christine Cassiano - Chief Corporate Affairs and Brand Strategy Officer
David Chang - President and Chief Executive Officer
Zachary Roberts - Executive Vice President of Research and Development and Chief Medical Officer
Geoff Parker - Chief financial officer
Conference Call Participants
Tyler Van Buren - TD Cowen
Salveen Richter - Goldman Sachs
Brian Cheng - JPMorgan
Jack Allen - Baird
John Newman - Canaccord Genuity
Kelsey Goodwin - Guggenheim
Reni Benjamin - JMP Securities
Kalpit Patel - B. Riley Securities
Luca Issi - RBC Capital
Laura Prendergast - Raymond James
William Pickering - Bernstein
Presentation
Operator
Thank you for standing by and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.
Christine Cassiano
Thank you, operator, and welcome to all who have joined this call. After the market closed today, Allogene issued a press release that provides a business update and financial results for the fourth quarter and full year 2023. This press release and today's webcast are both available on our website. Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person, as we will keep this call to an hour and do our best to get to as many questions as possible. Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief financial officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, and 2024 financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements....
Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript